Literature DB >> 6683185

Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro.

E O Pettersen, O Nome, O W Rønning, R Oftebro.   

Abstract

Synchronized cells of the human line NHIK 3025 were used to study inactivating and cell-cycle inhibitory effects induced by benzaldehyde. Inactivation was measured as loss of colony-forming ability after treatment of exponentially growing or synchronized cells. Cell-cycle inhibition was measured by flow cytometric recordings of DNA-histograms and microscopic recordings of cell division in synchronized cells. Treatment with benzaldehyde for 4 or 24 hr showed that a marked decrease in survival took place for concentrations above 6.4 mM. Cell-cycle inhibition was observed at concentrations as low as 0.8 mM. Synchronized cells were treated with 3.2 and 6.4 mM benzaldehyde for 8 hr starting at various stages of the cell-cycle. Both the colony-forming ability and the rate of cell-cycle traverse was measured. No difference in sensitivity was found whether the treatment was given in G1, S or in G2. Thus the results show that there is no specific part of interphase where the cells are particularly sensitive with respect to either the inactivating or the cell-cycle inhibitory effects of benzaldehyde in concentrations up to 6.4 mM. When benzaldehyde was present during mitosis both the inactivating and the cell-cycle inhibitory effects were markedly enhanced as compared to the corresponding effects during interphase. It is concluded that benzaldehyde must affect some process within the cell which represents a general requirement for cell-cycle progression. In addition, there are effects on processes that take place only during the last few minutes before and/or during mitosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683185     DOI: 10.1016/0277-5379(83)90114-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats.

Authors:  J M Dornish; R O Larsen; P E Schwarze; B Børretzen; E O Pettersen
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137.

Authors:  M E Juul; J M Dornish; P E Schwarze; E O Pettersen; R Oftebro
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

3.  Inhibition of experimental pulmonary metastasis in mice by beta-cyclodextrin-benzaldehyde.

Authors:  H Ochiai; S Niwayama; K Masuyama
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.

Authors:  C B Dunsaed; J M Dornish; E O Pettersen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  4, 6-0-benzylidene-D-glucopyranose (BG) in the treatment of solid malignant tumours, an extended phase I study.

Authors:  T Tatsumura; M Tsujimoto; S Koyama; T Furuno; Y Komori; H Sato; K Yamamoto; M Kitagawa; S Kagamimori
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

6.  Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H).

Authors:  E O Pettersen; R O Larsen; J M Dornish; B Børretzen; M E Juul; T E Aastveit; J M Nesland; E K Rofstad; R Oftebro
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

7.  Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.

Authors:  J M Dornish; E O Pettersen; R Oftebro
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

8.  Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia.

Authors:  E O Pettersen; T Lindmo
Journal:  Br J Cancer       Date:  1983-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.